G

Glenmark Pharmaceuticals Ltd
NSE:GLENMARK

Watchlist Manager
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
Watchlist
Price: 1 535.8 INR -1.11%
Market Cap: 433.4B INR
Have any thoughts about
Glenmark Pharmaceuticals Ltd?
Write Note
GLENMARK
/
Balance Sheet
/
Other Long-Term Assets

Glenmark Pharmaceuticals Ltd
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Glenmark Pharmaceuticals Ltd
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
G
Glenmark Pharmaceuticals Ltd
NSE:GLENMARK
Other Long-Term Assets
₹11.9B
CAGR 3-Years
-11%
CAGR 5-Years
-5%
CAGR 10-Years
17%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Other Long-Term Assets
₹18.6B
CAGR 3-Years
24%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Other Long-Term Assets
₹8.3B
CAGR 3-Years
-8%
CAGR 5-Years
2%
CAGR 10-Years
19%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Other Long-Term Assets
₹46.8B
CAGR 3-Years
11%
CAGR 5-Years
4%
CAGR 10-Years
13%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Other Long-Term Assets
₹6.1B
CAGR 3-Years
13%
CAGR 5-Years
7%
CAGR 10-Years
15%
M
Mankind Pharma Ltd
NSE:MANKIND
Other Long-Term Assets
₹1.1B
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Glenmark Pharmaceuticals Ltd
Glance View

Market Cap
433.4B INR
Industry
Pharmaceuticals

Glenmark Pharmaceuticals Ltd., founded in 1977 by Gracias Saldanha, has crafted its journey from a single-product company to a noteworthy player in the global pharmaceutical landscape. Headquartered in Mumbai, India, its growth has been driven by a formidable strategy of focusing on both generics and novel drug discovery. In the fiercely competitive world of pharmaceuticals, Glenmark carved its niche by building a diverse product portfolio that spans across dermatology, respiratory, and oncology segments, among others. The company’s nuanced understanding of therapeutic areas and its pursuit of complex generics have empowered it to not only tap into established markets but also venture into emerging ones across 80 countries. This international strategy, combined with robust research and development infrastructure, underscores how Glenmark leverages scientific innovation to ensure steady revenue streams. At the heart of Glenmark's operations lies its commitment to research-driven growth. The company allocates significant resources to its R&D initiatives, manifesting in state-of-the-art facilities across India, Switzerland, and the U.S. Through these centers, Glenmark focuses on the development of differentiated generic medicines and the discovery of innovative therapeutic molecules. The synergy between its generic and innovative drug segments enables Glenmark to sustain profitability by capitalizing on patent expiries while simultaneously pioneering novel drug therapies. This dual approach not only helps the company secure a competitive position in the pharmaceutical market but also fuels its earnings through a balanced mix of volume-driven sales and premium pricing of differentiated products.

GLENMARK Intrinsic Value
1 053.31 INR
Overvaluation 31%
Intrinsic Value
Price
G
What is Intrinsic Value?

See Also

What is Glenmark Pharmaceuticals Ltd's Other Long-Term Assets?
Other Long-Term Assets
11.9B INR

Based on the financial report for Sep 30, 2024, Glenmark Pharmaceuticals Ltd's Other Long-Term Assets amounts to 11.9B INR.

What is Glenmark Pharmaceuticals Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
17%

Over the last year, the Other Long-Term Assets growth was -74%. The average annual Other Long-Term Assets growth rates for Glenmark Pharmaceuticals Ltd have been -11% over the past three years , -5% over the past five years , and 17% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.